Mats Lindskog

Director/Board Member at WNTRESEARCH AB

Health Technology

Consumer Services

Profile

Mats Lindskog is currently working as a Director at Wntresearch AB and as a Chief Business Officer at Oblique Therapeutics AB.
He holds a doctorate degree from the Royal Institute of Technology.

Mats Lindskog active positions

Companies	Position	Start
WNTRESEARCH AB	Director/Board Member	31/12/2022
Oblique Therapeutics AB Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.	Corporate Officer/Principal	-

All active positions of Mats Lindskog

Training of Mats Lindskog

Royal Institute of Technology

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mats Lindskog's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
WNTRESEARCH AB	Health Technology

Private companies	1
Oblique Therapeutics AB Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.	Health Technology